Terms: = Uterine cancer AND SET, I2PP2A, 6418, ENSG00000119335, TAF-IBETA, PHAPII, IGAAD, 2PP2A AND Prognosis
263 results:
1. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-PD-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
2.
Zhang YT; Xu LJ; Li L
Genet Test Mol Biomarkers; 2024 Jan; 28(1):10-21. PubMed ID: 38294357
[No Abstract] [Full Text] [Related]
3. Systematic pan-cancer analysis of RNF186 with potential implications in progression and prognosis in human cancer.
Hu Y; Jiang N; Wang X; Wu X; Bo J; Chen Y; Zeng Y; Wei X; Zhang H; Li M
Life Sci; 2024 Feb; 338():122389. PubMed ID: 38160786
[TBL] [Abstract] [Full Text] [Related]
4. [Expression of ProEXC and PRMT5 in cervical adenocarcinoma and their clinical significance].
Cui HX; Lou XL; Xia W; Zhang YS; Cheng XY; Deng LF
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(48):3967-3971. PubMed ID: 38129175
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer.
Wang J; Wang S; Wang J; Huang J; Lu H; Pan B; Pan H; Song Y; Deng Q; Jin X; Shi G
Cancer Med; 2023 Dec; 12(24):22381-22394. PubMed ID: 38087815
[TBL] [Abstract] [Full Text] [Related]
6. Identification of prognostic biomarkers for cervical cancer based on programmed cell death-related genes and assessment of their immune profile and response to drug therapy.
Feng S; Wang Z; Zhang H; Hou B; Xu Y; Hao S; Lu Y
J Gene Med; 2024 Jan; 26(1):e3643. PubMed ID: 38044747
[TBL] [Abstract] [Full Text] [Related]
7. IRX2 regulates endometrial carcinoma oncogenesis by transcriptional repressing RUVBL1.
Xu Q; Zhou W; Zhou Y; Zhang X; Jiang R; Ai Z; Chen J; Ma L
Exp Cell Res; 2024 Jan; 434(1):113866. PubMed ID: 38042247
[TBL] [Abstract] [Full Text] [Related]
8. Development and validation of a prognostic nomogram model incorporating routine laboratory biomarkers for preoperative patients with endometrial cancer.
Cong R; Li M; Xu W; Ma X; Wang S
BMC Cancer; 2023 Nov; 23(1):1167. PubMed ID: 38031022
[TBL] [Abstract] [Full Text] [Related]
9. Conduction and validation of a novel prognostic signature in cervical cancer based on the necroptosis characteristic genes via integrating of multiomics data.
Xu T; Jiang J; Xiang X; Jahanshahi H; Zhang Y; Chen X; Li L
Comput Biol Med; 2024 Jan; 168():107656. PubMed ID: 38029530
[TBL] [Abstract] [Full Text] [Related]
10. Development and validation of a nomogram to predict overall survival for cervical adenocarcinoma: A population-based study.
Fa XY; Yang YJ; Niu CC; Yu YJ; Diao JD
Medicine (Baltimore); 2023 Nov; 102(47):e36226. PubMed ID: 38013281
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic evaluation of the novel blueprint of DNA methylation sites by integrating bulk RNA-sequencing and methylation modification data in endometrial cancer.
Zhou H; Zhang Y; Jin J; Shen K; Yang Y; Lao P
J Gene Med; 2024 Jan; 26(1):e3638. PubMed ID: 38011892
[TBL] [Abstract] [Full Text] [Related]
12. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
13. Identification of the role of endoplasmic reticulum stress genes in endometrial cancer and their association with tumor immunity.
Zhang TA; Zhang Q; Zhang J; Zhao R; Shi R; Wei S; Liu S; Zhang Q; Wang H
BMC Med Genomics; 2023 Oct; 16(1):261. PubMed ID: 37880674
[TBL] [Abstract] [Full Text] [Related]
14. Disulfidptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial cancer.
Shi S; Tang X; Liu H
Reprod Sci; 2024 Mar; 31(3):811-822. PubMed ID: 37880552
[TBL] [Abstract] [Full Text] [Related]
15. BUB1, BUB1B, CCNA2, and CDCA8, along with miR-524-5p, as clinically relevant biomarkers for the diagnosis and treatment of endometrial carcinoma.
Hao Q; Wu H; Liu E; Wang L
BMC Cancer; 2023 Oct; 23(1):995. PubMed ID: 37853361
[TBL] [Abstract] [Full Text] [Related]
16. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
17. The prognostic, immunological and single-cell features of m6A molecules in cervical cancer.
Zhu X; Song X; Chen Q; Peng Y; Shi F
Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):89-99. PubMed ID: 37807329
[TBL] [Abstract] [Full Text] [Related]
18. Pathogenomics model for personalized medicine in cervical cancer: Cross-talk of gene expressions and pathological images related to oxidative stress.
Li J; Chen S; Wu J; Liu X; Liu H; Liu Y; Zhu Z
Environ Toxicol; 2024 Feb; 39(2):751-767. PubMed ID: 37755325
[TBL] [Abstract] [Full Text] [Related]
19. A Novel Eight-Gene Signature for Lipid Metabolism Predicts the Progression of Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma.
Wang S; Zhang S
Reprod Sci; 2024 Feb; 31(2):514-531. PubMed ID: 37749448
[TBL] [Abstract] [Full Text] [Related]
20. Characterization of tumor microenvironment and tumor immunology based on the double-stranded RNA-binding protein related genes in cervical cancer.
Li J; Wan C; Li X; Quan C; Li X; Wu X
J Transl Med; 2023 Sep; 21(1):647. PubMed ID: 37735483
[TBL] [Abstract] [Full Text] [Related]
[Next]
